Ciglitazone
Ciglitazone is a thiazolidinedione that exhibits antihypertensive, anticancer, and anti-diabetic activities. Ciglitazone acts as an agonist at PPARγ receptors, decreasing insulin levels, VEGF production, and blood pressure. In cellular models of stomach cancer, ciglitazone induces G1 phase cell cycle arrest, inhibits ERK phosphorylation, and suppresses cell growth.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18851903
| Cas No. |
74772-77-3 |
|---|---|
| Purity |
≥98% |
| Formula |
C18H23NO3S |
| Formula Wt. |
333.45 |
| Chemical Name |
(+/-)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione |
| IUPAC Name |
5-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| Melting Point |
114-130°C |
| Solubility |
Soluble in DMSO or ethanol. |
| Appearance |
Tan solid |
Shah DK, Menon KM, Cabrera LM, et al. Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. Fertil Steril. 2010 Apr;93(6):2042-7. PMID: 19342033.
Cheon CW, Kim DH, Kim DH, et al. Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20. PMID: 19140230.
Pershadsingh HA, Szollosi J, Benson S, et al. Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension. 1993 Jun;21(6 Pt 2):1020-3. PMID: 8505086.
